Celgene Corporation (CELG) : $112.27 million worth of transactions were on upticks in Celgene Corporation (CELG), compared to $90.44 million on downticks. The ratio between the two was 1.24, whereas, the net money flow stood at a healthy $21.83 million on Thursdays session.The block trades show a bullish bias with only $9.33 million worth of transactions done on downticks. The consistent buying on upticks in the stock accounted for $32.27million worth of trades. The up-down ratio between the uptick and downtick was 3.46, confirming that the stronger hands have been buying the stock on every weakness. The total money flow into the stock stood at $22.94 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.33%. The stock was trading at $101.42, with a drop of $0.34 over the previous days close. The stock recorded -3.44% for the week.
The stock has recorded a 20-day Moving Average of 1.2% and the 50-Day Moving Average is 0.66%. Shares have dropped -14.46% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $140.72 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $102.42 and the 200 Day Moving Average price is recorded at $103.84.
Celgene Corporation (NASDAQ:CELG): The stock opened at $102.95 on Thursday but the bulls could not build on the opening and the stock topped out at $103.14 for the day. The stock traded down to $100.86 during the day, due to lack of any buying support eventually closed down at $101.42 with a loss of -0.33% for the day. The stock had closed at $101.76 on the previous day. The total traded volume was 5,392,013 shares.
In an insider trading activity,The director officer (see remarks) of Celgene Corp /De/, Hugin Robert J sold 75,000 shares at $100.16 on June 20, 2016. The Insider selling transaction had a total value worth of $7,512,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.